Last Updated: August 10, 2026

Claims for Patent: 10,119,132

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,119,132

Title:	Long-acting coagulation factors and methods of producing same
Abstract:	Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
Inventor(s):	Fima; Udi Eyal (Dvira, IL), Hart; Gili (Shoham, IL)
Assignee:	OPKO Biologics Ltd. (Kiryat Gat, IL)
Application Number:	14/948,890
Patent Claims:	1. A method of treating hemophilia A in a subject, the method comprising administering a CTP-modified Factor VII (FVII) polypeptide to said subject, wherein said CTP-modified Factor VII (FVII) polypeptide consists of a coagulation Factor VII (FVII) polypeptide and three chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation FVII polypeptide, thereby treating said hemophilia A. 2. The method of claim 1, wherein at least one CTP consists of the amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 3. The method of claim 1, wherein at least one CTP is glycosylated. 4. The method of claim 1, wherein at least one CTP is attached to said coagulation Factor VII polypeptide via a linker. 5. The method of claim 4, wherein said linker is a peptide bond. 6. The method of claim 1, wherein the sequence of said CTP-modified FVII polypeptide is selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO: 46. 7. The method of claim 1, wherein said coagulation FVII polypeptide is an activated coagulation FVII (FVIIa) polypeptide. 8. The method of claim 7, wherein said activated coagulation FVII polypeptide is in the form of a disulfide-linked two chain heterodimer. 9. The method of claim 1, wherein the subject is a human child. 10. The method of claim 1, wherein said administering is via the subcutaneous route. 11. A method of treating hemophilia B in a subject, the method comprising the step of administering to the subject a CTP-modified Factor IX (FIX) polypeptide, wherein the CTP-modified Factor IX (FIX) polypeptide consists of a coagulation Factor IX (FIX) polypeptide and three chorionic gonadotrophin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation FIX polypeptide, thereby treating said hemophilia B in said subject. 12. The method of claim 11, wherein the sequence of said CTP-modified Factor IX (FIX) polypeptide is selected from the group consisting of SEQ ID NO: 31 and SEQ ID NO: 48. 13. The method of claim 11, wherein at least one CTP consists of the amino acid sequence selected from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 14. The method of claim 11, wherein at least one CTP is glycosylated. 15. The method of claim 11, wherein at least one CTP is truncated. 16. The method of claim 11, wherein at least one CTP is attached to said coagulation FIX polypeptide via a linker. 17. The method of claim 16, wherein said linker is a peptide bond. 18. The method of claim 11, wherein said coagulation FIX polypeptide is an activated coagulation FIX (FIXa) polypeptide. 19. The method of claim 18, wherein said activated coagulation FIX polypeptide is in the form of a disulfide-linked two chain heterodimer. 20. The method of claim 11, wherein the subject is a human child. 21. The method of claim 11, wherein said administering is via the subcutaneous route.

Details for Patent 10,119,132

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,119,132	2035-11-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,119,132	2035-11-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,119,132	2035-11-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.